Anti-NF-κB and anti-inflammatory activities of synthetic isothiocyanates: Effect of chemical structures and cellular signaling

Chemico-Biological Interactions

Volumn 179, Issue 2-3, 2009, Pages 202-211

  Prawan, Auemduan ^a,b   Saw, Constance Lay Lay ^a   Khor, Tin Oo ^a   Keum, Young Sam ^a   Yu, Siwang ^a   Hu, Longqin ^a   Kong, Ah Ng ^a  

^a RUTGERS UNIVERSITY   (United States)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Anti inflammatory response; Cancer chemopreventive compounds; Isothiocyanates; NF B; Nrf2

Indexed keywords

3 MORPHOLINOPROPYLISOTHIOCYANATE; 3,4 METHYELENDIOXYBENZYLISOTHIOCYANATE; BACTERIUM LIPOPOLYSACCHARIDE; CYCLOOXYGENASE 2; CYTOKINE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOTHIOCYANIC ACID DERIVATIVE; METHYL 3 ISOTHIOCYANATOPROPIONATE; PHENYLETHYLISOTHIOCYANATE; TETRAHYDROFURFURYLISOTHIOCYANATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ISOTHIOCYANIC ACID; LIPOPOLYSACCHARIDE; LUCIFERASE; MESSENGER RNA; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG STRUCTURE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; BIOSYNTHESIS; CELL SURVIVAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; GENETICS; METABOLISM; REPORTER GENE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

BACTERIA (MICROORGANISMS); MURINAE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, REPORTER; HUMANS; INFLAMMATION; ISOTHIOCYANATES; LIPOPOLYSACCHARIDES; LUCIFERASES; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 62549085979     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.12.014     Document Type: Article

References (47)

1. van Poppel G., Verhoeven D.T., Verhagen H., and Goldbohm R.A. Brassica vegetables and cancer prevention. Epidemiology and mechanisms. Adv. Exp. Med. Biol. 472 (1999) 159-168
2. Conaway C.C., Yang Y.M., and Chung F.L. Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. Curr. Drug Metab. 3 (2002) 233-255
3. Kristal A.R., and Lampe J.W. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr. Cancer 42 (2002) 1-9
4. Verhoeven D.T., Goldbohm R.A., van Poppel G., Verhagen H., and van den Brandt P.A. Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol. Biomarkers Prev. 5 (1996) 733-748
5. Myzak M.C., Dashwood W.M., Orner G.A., Ho E., and Dashwood R.H. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J. 20 (2006) 506-508
6. Khor T.O., Keum Y.S., Lin W., Kim J.H., Hu R., Shen G., Xu C., Gopalakrishnan A., Reddy B., Zheng X., Conney A.H., and Kong A.N. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res. 66 (2006) 613-621
7. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., Chiao P.J., Achanta G., Arlinghaus R.B., Liu J., and Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10 (2006) 241-252
8. Hu R., Khor T.O., Shen G., Jeong W.S., Hebbar V., Chen C., Xu C., Reddy B., Chada K., and Kong A.N. Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis 27 (2006) 2038-2046
9. Stoner G.D., Morrissey D.T., Heur Y.H., Daniel E.M., Galati A.J., and Wagner S.A. Inhibitory effects of phenethyl isothiocyanate on N-nitrosobenzylmethylamine carcinogenesis in the rat esophagus. Cancer Res. 51 (1991) 2063-2068
10. Yang Y.M., Conaway C.C., Chiao J.W., Wang C.X., Amin S., Whysner J., Dai W., Reinhardt J., and Chung F.L. Inhibition of benzo(a)pyrene-induced lung tumorigenesis in A/J mice by dietary N-acetylcysteine conjugates of benzyl and phenethyl isothiocyanates during the postinitiation phase is associated with activation of mitogen-activated protein kinases and p53 activity and induction of apoptosis. Cancer Res. 62 (2002) 2-7
11. Keum Y.S., Jeong W.S., and Kong A.N. Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat. Res. 555 (2004) 191-202
12. Xu C., Yuan X., Pan Z., Shen G., Kim J.H., Yu S., Khor T.O., Li W., Ma J., and Kong A.N. Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol. Cancer Ther. 5 (2006) 1918-1926
13. Hu R., Kim B.R., Chen C., Hebbar V., and Kong A.N. The roles of JNK and apoptotic signaling pathways in PEITC-mediated responses in human HT-29 colon adenocarcinoma cells. Carcinogenesis 24 (2003) 1361-1367
14. Kim J.H., Xu C., Keum Y.S., Reddy B., Conney A., and Kong A.N. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27 (2006) 475-482
15. Jeong W.S., Kim I.W., Hu R., and Kong A.N. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm. Res. 21 (2004) 661-670
16. Rose P., Won Y.K., Ong C.N., and Whiteman M. Beta-phenylethyl and 8-methylsulphinyloctyl isothiocyanates, constituents of watercress, suppress LPS induced production of nitric oxide and prostaglandin E2 in RAW 264.7 macrophages. Nitric Oxide 12 (2005) 237-243
17. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., and Lee S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 480/481 (2001) 243-268
18. Goossens L., Pommery N., and Henichart J.P. COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy. Curr. Top. Med. Chem. 7 (2007) 283-296
19. Meric J.B., Rottey S., Olaussen K., Soria J.C., Khayat D., Rixe O., and Spano J.P. Cyclooxygenase-2 as a target for anticancer drug development. Crit. Rev. Oncol. Hematol. 59 (2006) 51-64
20. Rao C.V. Nitric oxide signaling in colon cancer chemoprevention. Mutat. Res. 555 (2004) 107-119
21. Lala P.K., and Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2 (2001) 149-156
22. Jaiswal M., LaRusso N.F., and Gores G.J. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 281 (2001) G626-634
23. Kroncke K.D., Fehsel K., and Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin. Exp. Immunol. 113 (1998) 147-156
24. Wu K.K. Transcription-based COX-2 inhibition: a therapeutic strategy. Thromb. Haemost. 96 (2006) 417-422
25. Kawanishi S., Hiraku Y., Pinlaor S., and Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol. Chem. 387 (2006) 365-372
26. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18 (2000) 621-663
27. Muller J.M., Ziegler-Heitbrock H.W., and Baeuerle P.A. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 187 (1993) 233-256
28. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., and Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 72 (2006) 1605-1621
29. Nims R.W., Cook J.C., Krishna M.C., Christodoulou D., Poore C.M., Miles A.M., Grisham M.B., and Wink D.A. Colorimetric assays for nitric oxide and nitrogen oxide species formed from nitric oxide stock solutions and donor compounds. Methods Enzymol. 268 (1996) 93-105
30. Khor T.O., Huang M.T., Kwon K.H., Chan J.Y., Reddy B.S., and Kong A.N. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res. 66 (2006) 11580-11584
31. Prawan A., Keum Y.S., Khor T.O., Yu S., Nair S., Li W., Hu L., and Kong A.N. Structural influence of isothiocyanates on the antioxidant response element (ARE)-mediated heme oxygenase-1 (HO-1) expression. Pharm. Res. 25 (2008) 836-844
32. Naureckiene S., Edris W., Ajit S.K., Katz A.H., Sreekumar K., Rogers K.E., Kennedy J.D., and Jones P.G. Use of a murine cell line for identification of human nitric oxide synthase inhibitors. J. Pharmacol. Toxicol. Methods 55 (2007) 303-313
33. Dejardin E., Deregowski V., Chapelier M., Jacobs N., Gielen J., Merville M.P., and Bours V. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 18 (1999) 2567-2577
34. Xu C., Shen G., Chen C., Gélinas C., and Kong A.N. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene 24 (2005) 4486-4495
35. Huang S., Pettaway C.A., Uehara H., Bucana C.D., and Fidler I.J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 (2001) 4188-4197
36. Duffey D.C., Chen Z., Dong G., Ondrey F.G., Wolf J.S., Brown K., Siebenlist U., and Van Waes C. Expression of a dominant-negative mutant inhibitor-kBa of nuclear factor-kB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res. 59 (1999) 3468-3474
37. Wang C.Y., Cusack Jr. J.C., Liu R., and Baldwin Jr. A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5 (1999) 412-417
38. Keum Y.S., Jeong W.S., and Kong A.N. Chemopreventive functions of isothiocyanates. Drug News Perspect. 18 (2005) 445-451
39. Chen Y.R., Han J., Kori R., Kong A.N., and Tan T.H. Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase. J. Biol. Chem. 277 (2002) 39334-39342
40. Yu R., Jiao J.J., Duh J.L., Tan T.H., and Kong A.N. Phenethyl isothiocyanate, a natural chemopreventive agent, activates c-Jun N-terminal kinase 1. Cancer Res. 56 (1996) 2954-2959
41. Chen Y.H., Dai H.J., and Chang H.P. Suppression of inducible nitric oxide production by indole and isothiocyanate derivatives from Brassica plants in stimulated macrophages. Planta Med. 69 (2003) 696-700
42. Calzado M.A., Bacher S., and Schmitz M.L. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr. Med. Chem. 14 (2007) 367-376
43. Umezawa K. Inhibition of tumor growth by NF-kappaB inhibitors. Cancer Sci. 97 (2006) 990-995
44. Aggarwal B.B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71 (2006) 1397-1421
45. Uto T., Fujii M., and Hou D.X. 6-(Methylsulfinyl)hexyl isothiocyanate suppresses inducible nitric oxide synthase expression through the inhibition of Janus kinase 2-mediated JNK pathway in lipopolysaccharide-activated murine macrophages. Biochem. Pharmacol. 70 (2005) 1211-1221
46. Adcock I.M. Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch. Chest Dis. 52 (1997) 178-186
47. Lee S.H., Seo G.S., Kim J.Y., Jin X.Y., Kim H.D., and Sohn D.H. Heme oxygenase 1 mediates anti-inflammatory effects of 2′,4′,6′-tris(methoxymethoxy) chalcone. Eur. J. Pharmacol. 532 (2006) 178-186